New research suggests that Ozempic and similar weight loss medications have the potential to be as big a game changer in ...

More and more people are taking weight loss injectables like Wegovy — but not everyone prescribed these drugs should have ...

Wall Street is bullish on Viking, but the company still has a lot to prove. Viking has a number of different clinical studies ...

Being a long-term investor isn't always easy, as you'll inevitably encounter downturns as well as the thriving bull periods that occur in a cyclical market. However, this is a far better alternative ...

We recently compiled a list of the 10 Most Promising Dividend Stocks According to Hedge Funds. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against ...

Truveta’s groundbreaking study analyzing real-world use of GLP-1 receptor agonist (GLP-1 RA) therapies in adults with overweight or obesity has published in JAMA Network Open, offering critical ...

For people with diabetes, the use of GLP-1 RAs is associated with a reduced risk for certain disorders and conditions, including neurocognitive and cardiometabolic disorders, and with an increased ...

Websites that sell compounded GLP-1 RAs often partially inform or misinform consumers, including with respect to US FDA approval.

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

The digital health unicorn sells its chronic condition management and musculoskeletal programs to employers and health plans ...

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) ...

With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...